To describe the retinal microvasculature of the eyes with nonarteritic retinal artery occlusion (RAO) based on optical coherence tomography angiography.
Cross-sectional, prospective, observational study performed from September 2014 through February 2015. En face projection of optical coherence tomography angiography images centered at the macula and optic disk of the eyes presenting with RAO were acquired using the RTVue XR Avanti with AngioVue software. Qualitative analysis of the morphology of the superficial and deep retinal capillary plexuses, and radial peripapillary capillaries was performed. Retinal vasculature images using optical coherence tomography angiography were correlated with fluorescein angiography images.
Seven patients (seven eyes) were enrolled in the study, including three eyes with central RAO and four eyes with branch RAO. Distinct differences in the distribution of zones of decreased vascular perfusion between the superficial and deep retinal capillary plexus corresponding to areas of delayed dye perfusion on fluorescein angiography were demonstrated in 6 of 7 (86.5%) eyes.
This small series suggests that optical coherence tomography angiography imaging can accurately discern retinal capillary plexuses at different levels in the eyes with RAO and may be sensitive for more precisely characterizing the extent of macular ischemia and monitoring vascular flow changes during the course of the disease.
A prototype optical coherence tomography angiography system based on spectral-domain optical coherence tomography was employed to characterize superficial and deep retinal vascular plexus in eyes with retinal artery occlusion.
*New England Eye Center and Tufts Medical Center, Tufts University, Boston, Maryland;
†CAPES Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil;
‡Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Maryland;
§Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California;
¶Doheny Eye Institute, Los Angeles, California;
**Stein Eye Institute, Los Angeles, California; and
††Greater Los Angeles VA Healthcare Center, Los Angeles, California.
Reprint requests: Nadia K. Waheed, MD, MPH, New England Eye Center at Tufts Medical Center, 260 Tremont Street, Biewend Building, 9–11th Floor, Boston, MA 02116; e-mail: firstname.lastname@example.org
Supported in part by a Research to Prevent Blindness Unrestricted grant to the New England Eye Center/Department of Ophthalmology, Tufts University School of Medicine, and Massachusetts Lions Club.
Dr. S. R. Sadda is a consultant for Allergan, Genentech, Carl Zeiss Meditec, Optos, Alcon, Novartis, Regeneron, Roche. Dr. D. Sarraf is a consultant for Genentech and has been loaned the Optovue machine with SSADA capability from Optovue Inc for research purposes. J. S. Duker is a consultant for and receives research support from Carl Zeiss Meditec, OptoVue, and Topcon Medical Systems Inc and has stock in Hemera Biosciences Inc, EyeNetra, and Ophthotech Corp. N. K. Waheed was a consultant for Iconic therapeutics, served the speaker's bureau for Thrombogenics, and receives research support from Carl Zeiss Meditec. None of the remaining authors have any financial/conflicting interests to disclose.